Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

The European Commission (EC) has granted approval to Bristol Myers Squibb’s (BMS) perioperative regimen of neoadjuvant Opdivo ...

BioMarin Pharmaceutical has signed a definitive agreement to acquire Inozyme Pharma in an all-cash transaction valued at ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

The US FDA has approved Incyte’s Zynyz (retifanlimab-dlwr) in conjunction with carboplatin and paclitaxel (platinum-based ...

In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, ...

Imagene is the Innovation award winner in the Precision Oncology category in the 2025 Pharmaceutical Excellence Awards.

Explore Novotech CEO John Moller's insights on the company's global expansion, commitment to diversity, and innovative ...